Christopher Nardo - Concepedia

Concepedia

Author

Christopher Nardo

Allergan (United States)

Also Known As

C J NARDO, C Nardo, C. J. Nardo, C. Nardo, Christopher J Nardo, Christopher J. Nardo, Christopher Nardo, Clelia Di Nardo

29

Publications

2.4K

Citations

10

H-Index

24

Concepts

All Affiliations

Allergan (United States)University of North Carolina at Chapel Hill Allergan (United Kingdom)University of Toronto Response Technologies (United States)

CN

About

Christopher Nardo is an author at Allergan (United States) specializing in medicine, cardiovascular disease, and cardiovascular reactivity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	654
2	Public Health	1	1	117
3	Epidemiology	1	1	117
4	Health Policy	1	1	117
5	Immunology	1	1	136

Christopher Nardo

×

10

Publications

2.4K

Citations

10

H-Index

	Year	Citations
Non–Insulin-Dependent Diabetes Mellitus and Fasting Glucose and Insulin Concentrations Are Associated With Arterial Stiffness Indexes Veikko Salomaa, Ward A. Riley, Jeremy D. Kark, Circulation	1995	578
OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid, European Urology Urological ResearchUrologyVoiding DysfunctionUrinary IncontinencePlacebo-controlled Trial	2013	401
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial Victor W. Νitti, Roger R. Dmochowski, Sender Herschorn, The Journal of Urology	2012	399
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial Victor W. Νitti, Roger R. Dmochowski, Sender Herschorn, The Journal of Urology	2016	328
Orthostatic hypotension and the incidence of coronary heart disease: the atherosclerosis risk in communities study K. M. Rose, Herman A. Tyroler, Christopher Nardo, American Journal of Hypertension	2000	244
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases Mark B. Faries, Nicola Mozzillo, Mohammed Kashani–Sabet, Annals of Surgical Oncology Tumor ImmunologySurgical OncologyCancer ImmunosurveillanceAdjuvant ImmunotherapyMedicine	2017	136
Descriptive Epidemiology of Blood Pressure Response to Change in Body Position Christopher Nardo, Lloyd E. Chambless, Kathleen C. Light, Hypertension HypertensionBody PositionBlood PressureBody CompositionKinesiology	1999	117
T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides Larry W. Moreland, Elizabeth E. Morgan, T. C. Adamson, Arthritis & Rheumatism	1998	73
OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder K.D. Sievert, Christopher R. Chapple, Sender Herschorn, International Journal of Clinical Practice	2014	63
Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide‐specific T‐cell responses in patients with multiple sclerosis Elizabeth E. Morgan, Christopher Nardo, Jocelyn P. Diveley, Journal of Neuroscience Research	2001	20

Page 1